FDA is investigating reports of T-cell malignancies, including chimeric antigen receptor (CAR) positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T-cell immunotherapies. fda.gov/vaccines-blood…
Ecstatic and proud to share the NICHE-2 results, now published in NEJM. Out of 111 pts, 95% had an MPR , and 68% a pCR after only 4 weeks of #neoadjuvant #immunotherapy. Grateful to the pts and colleagues who made this possible. John Haanen
nej.md/3Ku4X0H